The shadow of generic rivalry has repeatedly loomed above copyright’s blockbuster drug, Viagra, sparking questions about the outlook of related pharmaceutical holdings. While early periods saw impressive gains, the exclusivity lapse has opened the path for less expensive substitutes, possibly diminishing revenue and posing a significant hazard fo